New research reveals that parasite medications like mebendazole and fenbendazole—long ignored by Big Pharma—target the glutamine pathway in cancer cells, starving tumors just as they do parasites. These drugs are cheap, effective, and widely available—so what’s the catch?
According to Dr. Thomas Seyfried, the real barrier isn’t science, but profit. Pharmaceutical companies have a playbook: take a 50-cent pill, prove it fights cancer, then hike the price to $300. Sound familiar? (Looking at you, Martin Shkreli.)
The paradigm is shifting: cancer is a metabolic disease, not genetic. By understanding tumor metabolism and strategically combining drugs like 6-deoxynorleucine with existing therapies, we can outsmart cancer without bankrupting patients.
But here’s the kicker: no one’s being trained to think this way. The system is stuck chasing mutations while ignoring the metabolic roots of the disease. The revolution is here—if we dare to embrace it.
@jreichelt Wann kommt dieser Gehirntote Lauterbach endlich in den Knast oder wird nach Nord Korea etc verbannt , einfach zum kotzen dass der noch frei herumlaeuft